Novel Combination Approaches to Locoregional and Systemic Therapy in the Management of Primary and Metastatic Liver Tumors

被引：0

作者：

Dai, Michelle ^{[1
,2
]}

Tiu, Bryan-Clement Y. ^{[3
]}

Chen, Millennie ^{[4
]}

Sing, Caitlyn ^{[3
]}

Sharma, Vinay ^{[3
]}

Hoyos, Juan Pablo ^{[3
]}

Scherr, Riley ^{[3
]}

Lin, Wei Ju ^{[2
]}

Breuer, Joseph A. ^{[3
]}

Dayyani, Farshid ^{[5
]}

Imagawa, David ^{[6
]}

Abi-Jaoudeh, Nadine ^{[7
]}

机构：

[1] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA

[2] Touro Univ Nevada, Coll Osteopath Med, Henderson, NV 89014 USA

[3] Univ Calif Irvine, Sch Med, Irvine, CA USA

[4] Univ Calif Riverside, Sch Med, Riverside, CA USA

[5] Univ Calif Irvine, Dept Med, Div Hematol & Oncol, Orange, CA USA

[6] Univ Calif Irvine, Dept Surg, Orange, CA 92868 USA

[7] Univ Calif Irvine, Dept Radiol Sci, Orange, CA 92868 USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 12期

关键词：

Ablation; hepatocellular carcinoma; immune checkpoint inhibitor; radioembolization; transarterial chemoembolization; tyrosine kinase inhibitor; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; ADVANCED HEPATOCELLULAR-CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; PHASE-III; TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; NONALCOHOLIC STEATOHEPATITIS; DOUBLE-BLIND; SORAFENIB; CANCER;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several pathways and mutations must develop or be in place for the onset of cancer. Therefore, therapies should ideally target as many of these pathways as possible to improve outcomes. Combin-ing several agents has proven to be more effective than the use of monotherapy in the treatment of renal cell carcinoma, hepatocellular carcinoma, and other cancers. Combination therapy can also include locoregional therapies such as ablation and embolization with system-ic agents for synergistic effects. This review article discusses the current literature and clinical trials covering these multifactorial combination therapies in primary and metastatic liver tumors.

引用

页码：633 / 648

页数：16

共 50 条

[21] Combination therapy of IL-21 and radiation suppressed primary and metastatic tumors
Tao, M. -H
Lee, I. -J
Wu, P. -Y
Wu, C-J
EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 608 - 608
[22] Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies
Falvello, Virginia
Van Poznak, Catherine
CURRENT OSTEOPOROSIS REPORTS, 2021, 19 (04) : 452 - 461
[23] Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies
Virginia Falvello
Catherine Van Poznak
Current Osteoporosis Reports, 2021, 19 : 452 - 461
[24] Unknown primary tumors metastatic to liver
Ayoub, JP
Hess, KR
Abbruzzese, MC
Lenzi, R
Raber, MN
Abbruzzese, JL
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2105 - 2112
[25] The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors
Kreidieh, Malek
Zeidan, Youssef H.
Shamseddine, Ali
JOURNAL OF ONCOLOGY, 2019, 2019
[26] SIRT in primary and metastatic liver tumors
Hoffmann, M.
ONKOLOGIE, 2011, 34 : 287 - 287
[27] Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data
Shamimi-Noori, Susan
Gonsalves, Carin F.
Shaw, Colette M.
SEMINARS IN INTERVENTIONAL RADIOLOGY, 2017, 34 (02) : 145 - 166
[28] Systemic therapy for metastatic salivary gland tumors-challenges and novel concepts
Minichsdorfer, Christoph
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (04) : 400 - 404
[29] Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors
Gaba, Ron C.
Mendoza-Elias, Nasya
Morrison, Joseph D.
Valeshabad, Ali Kord
Lipnik, Andrew J.
SEMINARS IN INTERVENTIONAL RADIOLOGY, 2017, 34 (02) : 101 - 108
[30] SYSTEMIC ANGIOMATOSIS IN COMBINATION WITH PRIMARY MULTIPLE TUMORS
EGOROV, VP
ARKHIV PATOLOGII, 1990, 52 (03) : 61 - 64

← 1 2 3 4 5 →